Why Is CVS Group PLC Down Today?
CVS Group PLC shares fell 0.83% to 1,312.00p today, a decline of 11.00p, according to the supplied market data.
There was no new company announcement. The shares fell more than 6% on 24 September after FY26 results showed lower statutory profits and slower like-for-like growth in the second half, and investors remain cautious.
The vet sector continues to adjust to the outcome of the Competition and Markets Authority (CMA) market investigation.
Key Highlights
FY26 revenue rose 5.9% to £712.8m.
Adjusted EBITDA increased 5.1% to £141.5m, with a margin of 19.9%.
Adjusted EPS grew 6.9% to 85.6p, and adjusted pre-tax profit rose 7.6% to £84.9m.
Statutory pre-tax profit fell 1.8% to £32.0m due to £10.6m of exceptional costs.
The CMA's final remedies order was published on 22 September 2026, in line with expectations.
About CVS Group PLC
CVS is a UK-listed veterinary group and a leading provider of veterinary services in the UK, with a growing presence in Australia.
It operates first-opinion practices, referral centres, diagnostic laboratories and online pharmacy services.
LSE:CVSG moved from AIM to the Main Market of the London Stock Exchange in 2026.
Key Reasons Behind Today's Downtick
Second-half like-for-like sales growth slowed, raising questions about underlying demand in the UK vet market.
Exceptional costs included £1.7m relating to the CMA investigation, £5.1m for implementing remedies, including rebranding, and £3.8m for the move to the Main Market.
Today's small decline appears to reflect continued caution following the results.
CMA Clarity
The CMA's market investigation into pricing and transparency in the vet sector has concluded. CVS says most recommendations have been implemented or are in hand.
The final remedies provide regulatory certainty after a prolonged investigation, which management had described as unhelpful.
CVS has also engaged with the government's consultation on reform of the Veterinary Surgeons Act 1966.
Australia and Growth
CVS has further increased its scale in Australia, which provides geographic diversification and acquisition opportunities.
In the UK, it has focused on a consistent national brand, digital marketing and improving client service. Its client Net Promoter Score rose to 80.6 from 78.9.
The Economics of Veterinary Care
Pet ownership in the UK remains high, and owners increasingly treat pets as family members, supporting demand for higher-quality and more advanced care. Veterinary services have historically been resilient through economic cycles because many treatments are non-discretionary.
CVS's integrated model, which combines first-opinion practices with referral centres, laboratories and pharmacy services, allows it to capture more of each client's spending and improve efficiency.
Recruitment remains a key challenge for the sector. CVS increased the number of vets it employs by 4.5% on an underlying basis in a previous year, but nurse and support staff growth has been slower.
Lower Exceptional Costs Ahead
FY26 profits were held back by £10.6m of exceptional costs linked to the CMA investigation, implementing remedies and the move to the Main Market.
With the CMA process now concluded and the listing move complete, these one-off costs should fall substantially. That could allow statutory profits to grow more in line with adjusted earnings, improving the headline picture for investors.
Key Growth Catalysts
Recovery in like-for-like growth, Australian acquisitions, margin improvement and lower exceptional costs could support the shares.
Risks
Regulatory changes could limit pricing. Recruitment and retention of vets and nurses remain challenging.
Consumer spending pressure could reduce discretionary pet care.
Valuation
At 1,312.00p, CVS has a market capitalisation of approximately £886.15m.
On FY26 adjusted EPS of 85.6p, the shares trade at around 15.3 times trailing earnings.
What Investors Should Watch Next
Investors should watch like-for-like trends, Australian expansion, cost control and the interim results in early 2027.
Conclusion
CVS Group's 0.83% fall to 1,312.00p reflects caution after slower second-half growth. However, CMA clarity, adjusted earnings growth and Australian expansion support the investment case.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...